ROMO1 and Sepsis: To develop novel AMPs for the treatment of bacteremia or sepsis, we designed AMPR-11 originating from a putative pore-forming region (K58-R78) of Romo1, and we showed that a single dose of AMPR-11 was effective in a murine model of sepsis triggered by either methicillin-resistant S. aureus (MRSA) or clinically isolated carbapenem-resistant strains (P. aeruginosa, K. pneumoniae, and A. Baumannii) [18].